-

Cencora Elects Lori J. Ryerkerk to Its Board of Directors

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025.

“Ms. Ryerkerk’s experience in complex, global supply chains will further strengthen the Board’s expertise as we continue supporting the company’s long-term growth. Her appointment reflects the Cencora Board’s ongoing commitment to leaders who can help us contribute to driving stakeholder value,” said Mark Durcan, Lead Independent Director.

“Lori’s experience as a public company CEO, leading a global specialties chemical company with extensive operations and logistics, will bring valuable insight as we execute against our strategy and build on our leadership as an end-to-end healthcare services provider,” said Robert P. Mauch, President and Chief Executive Officer of Cencora.

Ms. Ryerkerk is the former Chairman, President and Chief Executive Officer of Celanese. She joined Celanese in 2019 and became Chairman in 2020. Prior to her role with Celanese, Ms. Ryerkerk spent over 25 years in manufacturing operations leadership roles, including Executive Vice President of Global Manufacturing at Shell Downstream Inc. She also currently serves on the Board of Directors of Eaton Corp. and Norfolk Southern. Ms. Ryerkerk earned her B.S. in Chemical Engineering from Iowa State.

About Cencora

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 51,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $290 billion in annual revenue. Learn more at investor.cencora.com

Contacts

Bennett S. Murphy
Senior Vice President, Head of Investor Relations & Treasury
bennett.murphy@cencora.com

Industry:

Cencora

NYSE:COR
Release Versions
English

Contacts

Bennett S. Murphy
Senior Vice President, Head of Investor Relations & Treasury
bennett.murphy@cencora.com

More News From Cencora

Cencora Reports Fiscal 2025 Second Quarter Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below...

Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Fin...

Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended. Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The con...
Back to Newsroom